A specific type of gene mutation affecting the LDL receptor has been found in many Finnish patients with familial hypercholesterolemia (FH). The mutant allele is characterized by a 9.5-kb deletion extending from intron 15 to exon 18. Molecular cloning and sequencing of a cDNA segment corresponding to the deleted allele indicated that the mutant receptor differs radically from the normal one because of loss of the domains encoded by exons 16, 17, and 18. The carboxy-terminal portion of the normal receptor, comprising the amino acids 750-839, has been replaced by an unrelated stretch of 55 amino acids. The mutant allele was found to occur in 23 (50%) of 46 unrelated FH patients with an established functional defect in the LDL receptor. In cultured fibroblasts from the FH patients with the 9.5-kb deletion, both receptor-mediated binding and internalization of 'l25-LDL were lower than normal, the former, on average, by 25%, and the latter, on average, by 50%.
Introduction
The pathogenesis of familial hypercholesterolemia (FH)' was shown by Brown and Goldstein (1) to be the genetically determined lack of functional LDL receptors. As the function of LDL receptors is to carry plasma LDL particles to their intracellular sites ofcatabolism, any mutation resulting in defective function of LDL receptors must impair clearance of plasma LDL. Such receptor-mediated impairment results in accumulation of LDL in the circulation and produces the clinical picture ofFH. This leads to the clinical sequelae of FH, such as premature coronary heart disease (2).
Studies on functional defects in LDL receptors have defined four different pathogenic entities leading to defective clearance ofplasma LDL: (a) defective synthesis ofthe mRNA for the receptor, (b) defective transport of the receptor precursors from the endoplasmic reticulum to the Golgi complex, (c) defective binding of LDL to the receptor, and (d) failure ofthe cells to internalize the receptor-bound LDL (1) . At the level of DNA structure, the cause of the disease has been found to be more heterogeneous than would be expected from the functional classification alone (1, (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) . The numerous mutations at the DNA level provide a spectrum oftools for learning more about the normal functioning of the receptor, but such diversity hampers attempts to develop diagnostic aids based on recombinant DNA techniques. This applies especially to genetically heterogeneous populations, which are likely to contain many different mutations of the LDL receptor gene. In genetically homogeneous populations, in contrast, the LDL receptor gene is likely to be affected by fewer mutations; hence, there is a higher probability that among the FH patients in such populations one specific type of LDL receptor mutation will be especially frequent (9, 12, 17) .
In genetic terms, the Finnish population forms a relative isolate and has its own panel of inherited diseases ( 18) . In this population a specific type of LDL receptor mutation has been found to occur in at least one-third of unrelated patients heterozygous for FH (19) . Restriction enzyme mapping of the mutant allele (19) and sequencing of a genomic DNA fragment containing the mutation point (15) suggest that this Finnish type of mutation is due to a deletion of -9 kb extending from intron 15 to exon 18. However, these studies did not permit an analysis of the exact structure of the carboxy-terminal portion of the mutated receptor protein, since it was not possible to determine whether intron 15 and part of exon 18 are cleaved off from the mature mRNA or preserved.
In this paper we report the detailed structure ofthe Finnish type of mutated LDL receptor. The functional characteristics of the altered receptor were also investigated. The mutation was found to alter the carboxy-terminal end of the receptor and to produce a phenotype in which internalization of LDL is defective.
Methods
Patients. In our search for heterozygotes for FH, we initially identified a total of 600 patients from the records of the Lipid Outpatient Clinic of the University Hospital of Helsinki, all having fasting serum total cholesterol levels 2 9.5 mmol/liter (2 370 mg/dl). For the study, we selected 46 patients using the following additional criteria: presence of primary hyperlipidemia; presence of tendon xanthomas; a hypercholesterolemic first-degree family member; and a positive history of premature coronary heart disease in the family. The (19) . One positive clone with an insert 2.4 kb in size was selected; this hybridized with an exon 15-specific oligonucleotide probe, but not with an exon 16-specific probe (15) . The insert was cleaved by Eco RI digestion and subcloned into the pGEM-4 vector for sequencing.
Polymerase chain reaction. For unequivocal determination of the cDNA sequence around the putative deletion point (15) , another strategy was used involving the DNA amplification technique with the aid of the thermoresistant polymerase enzyme (New England Biolabs, Beverly, MA). First, 2 MAg of poly(A)-containing RNA from patient FH 10 was used for synthesizing the first cDNA strand directed by an exon 18-specific primer (complementary to nucleotides from 3,604 to 3,621, 5'GGAAGCACTAGGTGGGCG3'; see references 25 and 26) . Second, the amplification reaction for these RNA-DNA hybrids was carried out using methods described by Saiki et al. (27) . One of the nucleotide primers (5CAGCTCCACAGCCGTAAGG3') extended from nucleotide 2,193 to nucleotide 2,211 of exon 15 (25, 26) and the other was the exon 18-specific primer used for the synthesis of the first cDNA strand (see above). 25 amplifying cycles were performed. Onethird of the amplified material was fractionated by electrophoresis on 1.2% agarose, and the amplified cDNA fragment (-600 bp in size) was eluted from the gel with a commercial kit (Geneclean, Bio 101 Inc., La Jolla, CA) and sequenced directly without further subcloning.
Sequencing. Sequencing of double-stranded DNA was performed by the dideoxynucleotide chain-termination method (28) , using the enzyme Sequenase (United States Biochemical Corp., Cleveland, OH). The first sequencing primer was selected from exon 15 (5'CAGCT-CCACAGCCGTAAGG3'; see above) and the second primer according to a stretch at the 3' end ofthe sequence that had been determined with the first primer (5ACCTTCTCTCACTTGGG3'). A hydropathicity plot of the amino acid sequence deduced from the cDNA was constructed with the algorithm described by Kyte and Doolittle (29), using a window of nine amino acids.
Isolation ofplasma lipoproteins and lipid assays. Any lipid-lowering drugs were withdrawn at least 4 wk before the blood samples were taken, and the patients were advised to continue their cholesterol-lowering diet. After an overnight fast, blood samples were collected in 0.1% EDTA, and plasma, the LDL fraction (d = 1.006-1.063 g/ml), and the HDL fraction (d = 1.063-1.215 g/ml) were isolated by sequential ultracentrifugation at 4°C (30) . Plasma total cholesterol, total triglycerides, and the cholesterol contents of isolated lipoprotein fractions were measured by colorimetric enzymatic methods (Boehringer Mannheim Biochemicals, Mannheim, FRG).
Preparative isolation and radioactive labeling ofLDL. Blood from healthy normolipidemic donors was collected in 0.1% EDTA, and the LDL fraction (d = 1.020-1.050 g/ml) and lipoprotein-deficient serum (LPDS; d > 1.21 g/ml) were prepared by sequential ultracentrifugation at 4°C (30) . LDL was radiolabeled with 1251I using the iodine monochloride method as modified for lipoproteins (31) . The specific activities of different preparations ranged from 32 to 168 cpm/ng protein.
Fibroblast cultures. Skin biopsies were taken from controls from the inguinal region, and from patients from the antecubital region. Fibroblasts were grown in monolayer and maintained in a humidified atmosphere (5% C02) at 37°C in 75-cm2 stock flasks containing 10 ml of standard growth medium. This medium consisted of Eagle's MEM supplemented with penicillin (100 U/ml), streptomycin (100 ,g/ml), 2 mM glutamine, and 10% (vol/vol) FCS (Gibco, Paisley, Scotland). The studies were undertaken between the 5th and 16th passages of the cultures.
Binding, internalization, and degradation oflabeled LDL. All experiments were performed according to a standard format. Confluent monolayers of fibroblasts from stock flasks were dissociated with a solution containing 0.05% trypsin and 0.02% EDTA, and seeded at a concentration of 1 X I05 cells/dish into 60 X 15-mm dishes containing 2 ml ofstandard growth medium (day 0). On day 3, when the cells were in early logarithmic growth, they were washed with Dulbecco's PBS, after which 2 ml of fresh medium containing 10% (vol/vol) human LPDS was added (final protein concentration, 5 mg/ml). The experiments were performed on day 5 when the cells had been incubated with LPDS for 48 h and were still preconfluent and actively dividing, as documented with [3H]thymidine. At this stage of cell growth no correlation was found between the number of cells per dish and the activity of the LDL receptors. The experiments were started by replacing the medium with fresh medium containing LPDS and '25I-labeled LDL (16 Mg protein/ml) in the absence or presence of a 20-fold excess of unlabeled LDL. The monolayers were incubated for 5 h at 37°C, after which the medium was removed and precipitated with TCA. The acid-soluble fraction was treated with hydrogen peroxide, extracted with chloroform to remove free iodine, and counted to determine the amount of '251-labeled acid-soluble material formed by the cells and released into the medium (degraded '251-LDL) (32). The monolayers were then treated with heparin and the amount of '25I-labeled LDL released by the heparin was counted to determine how much had been bound to the LDL receptors present on the cell surface (bound 1251I LDL) (33). After heparin treatment, the monolayers were dissolved in 0.2 N NaOH and an aliquot was counted to determine the amount of (Fig. 1) To ascertain the structure of the mutated protein corresponding to the deleted gene, a fibroblast cDNA library of a heterozygous FH patient (FH 10) was first constructed. Genomic cloning and partial sequencing of this mutant allele had earlier demonstrated that a DNA segment extending from intron 15 to exon 18 in the 3' region ofthe LDL receptor gene is deleted. In light of this information it was reasoned that the normal and mutant alleles could be separately identified from the cDNA library: cDNA clones containing the normal allele would hybridize with both exon 15-and exon 16-specific probes, while cDNA clones containing the mutant allele would only hybridize with an exon 15-specific probe. With this strategy, one positive clone containing a 2.4-kb cDNA insert corresponding to the mutant allele was identified.
DNA sequencing over the mutation site and the areas flanking this, whether performed with the cDNA clone (see above) or the amplified cDNA sequence (see Methods) as template, gave identical information (Fig. 2) . From its 5' end on, the nucleotide sequence of the mutant allele is identical with that of the normal one up to the last nucleotide of exon 15. After a stretch of 245 Fig. 3 . According to the present and published data (25, 26) , the size of the deletion is -9,500 bp. The mutant allele should direct the synthesis of a 4.5-kb mRNA species, i.e., one of a length not significantly different from that (4.2 kb) previously estimated on RNA hybridization blots (15) .
The hydropathicity profiles of the carboxy-terminal ends of the normal (amino acid sequence data from reference 25) and the mutant LDL receptor are illustrated in Fig. 4 . This part of the normal receptor is characterized by a strongly hydrophobic region of 22 amino acids that traverses the membrane and so anchors the receptor to the cell (25) . In the mutated receptor, in contrast, this part is replaced by a weakly hydrophobic region comprising two short stretches of 7 and 16 amino acids with mean hydropathicity indexes of 0.8 and 0.9, respectively (Figs. 2 and 4) . (Fig. 6) .
In the fibroblasts from the 23 patients with the heterozygous form of FH without the 9.5-kb deletion (Figs. 5 and 6, closed circles), the binding of I251-LDL was, on average, only about half of normal (Fig. 5) . Internalization (mean value, 48%) and degradation (mean value, 49%) of '25I-LDL were impaired approximately in proportion to the defect in binding. However, in terms of internalization efficiency, these FH heterozygotes were heterogeneous. Thus, some ofthe patients had a near-normal internalization index and could be categorized as "binding defective" (33), and some had a clearly low internalization index, and so could be designated as "internalization defective" (35) .
Plasma lipids and lipoproteins. Determination ofthe levels of plasma total cholesterol, plasma total triglycerides, LDL cholesterol, and HDL cholesterol failed to disclose any differences between the groups of FH heterozygotes with and without the 9.5-kb deletion (Table I ). In both groups of patients hyperlipidemia was due to accumulation of extra cholesterol in the lipoprotein fraction of density 1.006-1.063 g/ml, i.e., the LDL fraction.
Discussion
We found previously that about one-third of patients with FF1
in Finland have a common LDL receptor gene mutation due to a large deletion at the 3' coding region of the gene (19 (Fig. 2) . Many of the large rearrangements within the LDL receptor gene so far described involve Alu sequences at either one or both ends of the deletion (3, 6-8, 10, 11) . Two patients with FH had a large deletion in the 3' coding region of the LDL receptor gene, ranging from 5 (FH 274; see reference 3) to 7.8 kb (FH 781; see reference 10) in size. Both deletions extend from an Alu sequence in intron 15 to an Alu sequence in exon 18, but the Alu sequences involved are different (Fig. 7) . The mature mRNAs corresponding to these two alleles differ in length (10) . The location of these deletions is similar, but not identical, to that present in the FH-Helsinki allele. The FHHelsinki allele does not involve Alu sequences at either end of the deletion and it encodes a mRNA molecule that is shorter than those corresponding to the mutant genes in patients FH 274 and FH 781 (Fig. 7) . But although the three mutations differ at the DNA and RNA levels, the corresponding proteins are likely to be identical. In each case the splicing acceptor site in exon 18 has been deleted. Accordingly, the mature mRNA always includes a copy of the 5' part of intron 15, which in all three cases contains an identical stretch of 164 nucleotides continuing the reading frame of exon 15 before a termination codon (UAA) is reached (Fig. 7) .
In both of the patients studied by the Dallas group, fibroblast culture assay revealed defective internalization of LDL particles (3, 10 ceptors into coated pits and their subsequent internalization, but has also caused impairment of the attachment of the receptor to the cell membrane (Fig. 8) . Indeed, the carboxy-terminal domain of the mutant receptor has a relatively low hydropathicity index value, averaging < 1 (Fig. 4) , which does not fulfill the requirements for a membrane-spanning region (29) . It remains to be investigated whether the mutant receptors encoded by the FH-Helsinki allele are secreted into the culture medium and, if so, whether secretion of the mutant receptors takes place in vivo. The present study adds a third example to the category of LDL receptor gene mutations that are prevalent in a particular population and have been characterized in detail at the DNA level. In the majority of French Canadians with FH, the disease is due to a large deletion eliminating the promotor region and the first exon ofthe LDL receptor gene (12) . The Lebanese mutation created a premature termination codon at amino acid 660, which results in the synthesis of a truncated receptor protein (9) . In all three cases the enrichment of a specific mutant allele can easily be explained as a "founder gene" effect. The same explanation may apply to the high prevalence of a specific LDL receptor gene mutation in South Africa, as judged by haplotype analysis with restriction enzymes (17) ; the exact molecular defect in this allele has not yet been reported, however. In Lebanon and South Africa the prevalence ofFH is considered to be exceptionally high, with an estimated frequency of 1 in 100 (2, 9). Whether the prevalence of FH in Finland is also exceptionally high remains to be determined. The possible occurrence of the FH-Helsinki allele in other populations likewise remains to be studied. 
